More on CGEM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $12.98 |
|
|||
| Open | $13.07 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $13.74 | ||||
| Day Low | $12.79 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,318,179 | ||||
- William Blair on Cullinan Oncology Inc. (CGEM): 'We continue to see multiple opportunities for upside to Cullinan shares'
- Cullinan Oncology Inc. (CGEM) PT Raised to $46 at Clear Street
- Cullinan Therapeutics reports clinical trial data for autoimmune treatments
- Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
- Cullinan Therapeutics reports positive CLN-978 data at EULAR 2026
- Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
- Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
- Cullinan Therapeutics receives FDA orphan drug status for leukemia drug
- Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
- Cullinan Oncology (CGEM) Reiterated at Buy by Stifel on CLN-978 Data
Entities mentioned with CGEM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
